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Abstract
Consider an experiment, where a new drug is tested for the first time on human subjects -
healthy volunteers. Such experiments are often performed as dose-escalation studies: a set
of increasing doses is pre-selected, individuals are grouped into cohorts, and in each cohort,
the dose number i can be administered only if the dose number i− 1 has already been tested
in the previous cohort. If an adverse effect of a dose is observed, the experiment stops and
thus no subjects are exposed to higher doses. In this paper, we assume that the response
is affected both by the dose or placebo effects as well as by the cohort effects. We provide
optimal approximate designs for selected optimality criteria (E-,MV - and LV -optimality) for
estimating the effects of the drug doses compared with the placebo. In particular, we obtain
the optimality of Senn designs and extended Senn designs with respect to multiple criteria.
Keywords: dose-escalation studies; approximate designs; comparison with control; optimal
designs; block designs
1 Introduction
A dose-escalation study for a new drug consists of a series of trials, in which the drug is given
to cohorts of individuals, one cohort at a time. The experimenters select a finite number of
increasing doses of the drug that are to be tested and each subject is given either one of the
doses or the placebo. In particular, the subjects in the first cohort may be given only the
lowest dose or the placebo, the subjects in the second cohort only the two lowest doses or
the placebo, etc. If an adverse effect is observed, the experiment stops; therefore, no subjects
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are exposed to higher doses. These studies are often performed when a new drug is tried on
humans for the first time and thus the safety of the subjects is the main concern, especially
if the drug is given to healthy volunteers - hence the slowly escalating doses.
Bailey [2009], motivated by the failure of the Te Genero trial (see Senn et al. [2007]), con-
sidered designs for dose-escalation studies with quantitative responses. Bailey [2009] modelled
the dose-escalation studies as blocking experiments with design constraints, where the blocks
represented the cohorts, and the treatments were the placebo and the drug doses. Some gen-
eral principles that reduce variance were presented, as well as a wide range of well performing
designs for estimating a system of all pairwise comparisons of treatments. Haines and Clark
[2014] provided some numerical methods for constructing A-,MV -, D- and E-optimal designs
in the setting proposed by Bailey [2009].
In this paper, we adopt the model considered by Bailey [2009] and we study the optimal
approximate designs. The approximate, or continuous, designs do not determine the actual
numbers of subjects that are given the particular treatments; rather, they determine the
proportions of all subjects that are allocated to each combination of a cohort and a treatment.
Note that when a total number of subjects is selected, optimal or efficient exact designs
can usually be constructed from the optimal approximate designs, e.g., see Chapter 12 in
Pukelsheim [2006].
Senn in his commentary Senn [2009] argued that in each cohort the comparison of the
latest dose with the placebo is relevant, and proposed a corresponding latest variance (LV )
optimality criterion. This relevance, as noted by Senn [2009], follows from the fact that the
crucial decision whether to proceed to the next cohort or to stop the experiment is based on
the effect of the latest dose relative to the placebo. Following the argued relevance of the
comparisons with the placebo, we consider the problem of comparing doses of the drug with
the placebo, unlike Bailey [2009], who studied the set of all pairwise comparisons. Therefore,
the system of contrasts studied here is, in fact, a comparison of test treatments (drug doses)
with a control (placebo).
There is a large amount of literature on comparison with control in blocking experi-
ments, beginning with Bechhofer and Tamhane [1981] (e.g., see Majumdar and Notz [1983],
Majumdar [1996] and Kunert et al. [2010]). However, these standard results are not applicable
in the model considered in this paper, due to the dose-escalation constraints.
We consider the E- and MV -optimality criteria, as well as the latest variance (LV ) crite-
rion proposed by Senn [2009], and we obtain optimal designs for these criteria. In particular,
the Senn designs (which are designs that assign in each cohort half of the subjects to the
placebo and the other half to the latest dose, see Bailey [2009], Senn [1997]) stand out, be-
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cause they are optimal with respect to all of the aforementioned criteria. Moreover, we obtain
a complete characterization of the class of all E-optimal designs, which allows for selecting
the best E-optimal design with respect to a secondary criterion chosen by the experimenter.
1.1 Notation
The symbols 1n and 0n denote the column vectors of length n of ones and zeroes, respectively.
Furthermore, Jn := 1n1
T
n is the n × n matrix of ones, 0m×n := 0m0Tn is the m × n matrix
of zeroes and ei is the i-th standard unit vector (the i-th column of the identity matrix In,
where n is the dimension of ei). We use the symbols λmin(A) and λmax(A) to denote the
smallest and the largest eigenvalue, respectively, of a symmetric matrix A. We denote the
column space of a matrix A as C(A).
2 The Model
We consider the model formulated by Bailey [2009]. A new drug is to be tested on N individu-
als split into t cohorts. Each individual is given a treatment i, which is either the placebo (for
i = 0) or one of n ≥ 2 increasing doses of the drug (for i = 1, . . . , n), i.e., dose1 < . . . < dosen.
We assume that the safety or tolerability outcome, or in general, the measured effects of the
drug on the subjects, are quantitative. Furthermore, we assume additivity of treatment and
cohort effects, i.e.,
Yj = µ+ τi(j) + θk(j) + εj, j = 1, . . . , N, (1)
where N is the total number of subjects, Yj is the measured safety or tolerability response
for the j-th subject, µ is the overall mean, i(j) ∈ {0, . . . , n} is the treatment given to the j-th
subject (0 denotes the placebo, 1, . . . , n denote the escalating doses), k(j) ∈ {1, . . . , t} is the
cohort in which the j-th subject is; τi is the effect of the i-th treatment, θk is the effect of
the k-th cohort, and εj is the random error. The errors {εj} are assumed to have zero mean,
variance σ2 and they are assumed to be independent. Note that the model (1) is in fact a
blocking experiment, with cohorts as blocks, and the doses and the placebo as treatments.
Adopting the notation of Bailey [2009], we will consider two cases: standard designs, where
t = n and extended designs, where t = n+ 1.
Based on the relevance of comparing the latest dose with the placebo argued in Senn
[2009], we assume that the objective of the experiment is to compare the drug doses with the
placebo; i.e., to estimate τ1 − τ0, . . . , τn − τ0.
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Consider the general linear model
Yj = f
T (xj)β + εj, j = 1, . . . , N,
where xj ∈ X, which is the finite set of all experimental conditions. Then, an approximate
design (from now on, simply a design) ξ is a mapping from X to [0, 1], such that
∑
x∈X ξ(x) =
1. The moment matrix of a design ξ is M(ξ) =
∑
x∈X ξ(x)f(x)f
T (x). A design ξ is said to
be feasible for a system ATβ if C(A) ⊆ C(M(ξ)); in such a case, the system ATβ is said to
be estimable under ξ. The information matrix of a feasible design ξ for estimating ATβ is
NA(ξ) = (A
TM−(ξ)A)−1, see Pukelsheim [2006].
A feasible design ξ∗ ∈ Ξ, where Ξ is the set of all considered designs, is Φ-optimal if it
maximizes (alternatively, minimizes) a given function Φ(ξ) among all designs ξ ∈ Ξ. We will
omit the argument ξ in expressions, in which it is clear from the context.
In model (1), we have X = {0, . . . , n}×{1, . . . , t}, f(i, k) = (eTi+1, 1, eTk )T , β = (τT , µ, θT )T ,
where τ = (τ0, . . . , τn)
T and θ = (θ1, . . . , θt)
T . The objective of the experiment is to estimate
τ1−τ0, . . . , τn−τ0, which can be written as a system of contrasts QT τ , where QT = (−1n, In),
or, equivalently, ATβ, where AT =
(
QT , 0n×(t+1)
)
.
The value ξ(i, k) determines the proportion of all subjects that are assigned to cohort k
and given the treatment i. Let ri(ξ) :=
∑
k ξ(i, k) be the total proportion of the trials with
treatment i, i = 0, . . . , n, sk(ξ) :=
∑
i ξ(i, k) be the total proportion of the trials for cohort
k, k = 1, . . . , t and r(ξ) := (r0(ξ), . . . , rn(ξ))
T , s(ξ) := (s1(ξ), . . . , st(ξ))
T . Then, Nri is the
replication number of the i-th treatment, and Nsk is the size of the k-th cohort. Thus, r is
the vector of relative replication numbers and s is the vector of relative sizes of the cohorts.
The moment matrix of a design ξ is
M(ξ) =
[
M11 M12
MT12 M22
]
,
where M11 = diag(r); M12 =
(
r,X
)
, where X =
(
ξ(i, k)
)
i,k
; and
M22 =
[
1 sT
s diag(s)
]
.
Note that r = X1t and s = X
T 1n+1.
In accordance with Bailey [2009], we introduce some constraints on the set of considered
designs Ξ. For each k ∈ {1, . . . , n}, we have:
(i) ξ(i, k) = 0 for i > k. In cohort k, the highest allowed dose is k.
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(ii)
∑
i ξ(i, k) = 1/t.
The constraint (i) formalizes the gradual dose-escalation requirement. Furthermore, in (ii),
each cohort is assumed to be of the same size, saym. In the case of extended designs, the only
condition for cohort k = n+ 1 is (ii), i.e., the condition (ii) is assumed for all k ∈ {1, . . . , t}.
In other words, cohort n+1 of extended designs is an additional cohort that is subject to no
constraints other than the fixed cohort size.
From now on, we have Ξ = {ξ is feasible | ξ satisfies (i), (ii)}. Bailey [2009] considered an
additional constraint (iii) ξ(k, k) ≥ 1/N , i.e., in each cohort, the highest allowed dose must
be given to at least one subject. Since (iii) will naturally be satisfied by optimal designs, we
disregard this constraint.
From condition (ii) follows that s = 1t/t; thus, the matrix M22 is of rank t and the Schur
complement Mτ = M11 −M12M−22MT12 of M is
Mτ = diag(r) − tXXT ,
which may be viewed as the information matrix of ξ, when all the treatments are of equal
interest. For a general matrix Q of full column rank, the system QT τ is estimable under
ξ if and only if C(Q) ⊆ C(Mτ ). The information matrix of a feasible design for estimating
QT τ is given by NA(ξ) = (Q
TM−τ (ξ)Q)
−1, e.g., see Rosa and Harman [2016]. The inverse
of the information matrix NA(ξ) is proportional to the variance matrix of the least-squares
estimator of QT τ under ξ; more precisely, Varξ(Q̂T τ ) = N
−1
A (ξ)σ
2/N , where N is the total
number of subjects.
It is easy to check that the Schur complement for a given design ξ, and thus the information
matrix of ξ, would be the same if the constant term µ was not present in model (1). It follows
that our results hold even in a model without the constant term.
Recall that the experimental aim considered in this paper is the comparison of the drug
doses with the placebo. For a feasible design ξ, the information matrix for comparing the
doses with the placebo (i.e., comparing test treatments with a control) NA(ξ) is obtained
by deleting the first row and column of Mτ (e.g., see Bechhofer and Tamhane [1981] or
Giovagnoli and Wynn [1985]).
Let us denote
Mτ =
[
α bT
b C
]
, X =
[
zT
Z
]
(2)
where C is an n× n matrix and Z is an n× t matrix. Then,
NA(ξ) = C = diag(r1, . . . , rn)− tZZT , (3)
5
where Z =
(
ξ(i, k)
)
i=1,...,n;k=1,...,t
.
3 E-optimality
3.1 Standard Designs
A design is E-optimal if it maximizes the minimum eigenvalue λmin(NA(ξ)), which is equiva-
lent to minimizing λmax(N
−1
A (ξ)) (e.g., Pukelsheim [2006]; Atkinson et al. [2007]). In order to
provide E-optimal designs, we characterize the E-optimal relative replication numbers (treat-
ment proportions). From Theorem 1 and Theorem 6 by Rosa and Harman [2016], we obtain
the following lemma.
Lemma 1. Let ξ be an E-optimal design for comparing the drug doses with the placebo in
model (1) without design constraints. Then, ξ satisfies r0(ξ) = 1/2 and ri(ξ) = 1/(2n) for
i = 1, . . . , n.
A (standard) design that satisfies
ξ(0, k) = ξ(k, k) =
1
2n
for k ∈ {1, . . . , n},
and is zero otherwise is a Senn design (see Bailey [2009], Senn [1997]). In such a design, half
of the subjects in each cohort are assigned to the placebo and the other half are assigned
to the highest allowed dose for that cohort. Note that Senn designs satisfy Lemma 1, i.e.,
they achieve the E-optimal treatment proportions. We show that Senn designs are the unique
E-optimal standard dose-escalation designs.
i\k 1 2 3 4
0 1/8 1/8 1/8 1/8
1 1/8 0 0 0
2 0 1/8 0 0
3 0 0 1/8 0
4 0 0 0 1/8
Table 1: Senn design for n = 4 doses. i - treatment number, k - cohort number
Theorem 1. A standard design ξ is E-optimal for comparing drug doses with the placebo if
and only if ξ is a Senn design.
The proof of Theorem 1 and all other non-trivial proofs are given in the appendix.
3.2 Extended Designs
Since the extra cohort in extended designs provides additional freedom for the experimenter,
the class of E-optimal extended designs is richer, compared to the single E-optimal standard
design (for given n). The E-optimal extended designs can be completely characterized by the
following conditions: the designs assign the placebo to half of the subjects in each cohort, and
allocate each dose to the same total number of subjects, N/(2n). Note that the E-optimality
of standard designs can be described by the same conditions; however, in the standard design
case, the Senn designs are the only ones that satisfy these conditions. Recall that t = n+ 1
in the extended design case.
Theorem 2. An extended design ξ is E-optimal for comparing the drug doses with the placebo
if and only if it satisfies ξ(0, k) = 1/(2t) for k = 1, . . . , n+1 and r1(ξ) = . . . = rn(ξ) = 1/(2n).
The standard Senn designs can be extended to obtain E-optimal extended designs. We
say that a uniformly extended Senn design is a design that satisfies
ξ(0, k) =
1
2t
for k = 1, . . . , n+ 1, ξ(i, i) =
1
2t
and ξ(i, n+ 1) =
1
2nt
for i = 1, . . . , n,
and is zero otherwise, see Table 2. Such a design is given by the standard Senn design in
the first n cohorts. In the last cohort, half of the subjects are assigned to the control and
the other half are uniformly distributed among all other treatments. The uniformly extended
Senn designs obviously satisfy the conditions of Theorem 2 and thus are E-optimal.
i\k 1 2 3 4 5
0 1/10 1/10 1/10 1/10 1/10
1 1/10 0 0 0 1/40
2 0 1/10 0 0 1/40
3 0 0 1/10 0 1/40
4 0 0 0 1/10 1/40
Table 2: Uniformly extended Senn design for n = 4 doses. i - treatment number, k - cohort
number
However, the class of E-optimal extended dose-escalation designs does not contain only
the uniformly extended Senn designs. The complete characterization of E-optimal extended
designs in Theorem 2 by linear constraints allows one to choose the best E-optimal design with
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respect to some secondary criterion, such as other optimality criteria (e.g., the well known
criteria of D- and A-optimality; for their definitions see Pukelsheim [2006]).
Because the provided characterization of E-optimal extended designs is linear, we can
employ an efficient convex optimization method from Harman and Sagnol [2015] to construct
A-optimal or D-optimal designs within the class of all E-optimal designs:
Example 1. Let n = 4. Then, the A-optimal and D-optimal designs in the class of all
E-optimal extended designs are given in Tables 3 and 4, respectively.
i\k 1 2 3 4 5
0 0.1000 0.1000 0.1000 0.1000 0.1000
1 0.1000 0.0219 0.0031 0.0000 0.0000
2 0 0.0781 0.0287 0.0091 0.0091
3 0 0 0.0682 0.0284 0.0284
4 0 0 0 0.0625 0.0625
Table 3: A-optimal design in the class of all E-optimal extended designs. i - treatment
number, k - cohort number
i\k 1 2 3 4 5
0 0.1000 0.1000 0.1000 0.1000 0.1000
1 0.1000 0.0248 0.0002 0.0000 0.0000
2 0 0.0752 0.0339 0.0079 0.0079
3 0 0 0.0659 0.0296 0.0296
4 0 0 0 0.0625 0.0625
Table 4: D-optimal design in the class of all E-optimal extended designs. i - treatment
number, k - cohort number
3.3 Interpretation of E-optimality for Dose-Escalation
Majumdar and Notz [1983], who pioneered the use of the optimality criteria in design of
experiments for comparing test treatments with a control, noted that E-optimality “does
not seem to posses a very natural statistical meaning [for the comparison with a control]”.
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Since then, the criterion received little attention in design literature on the comparison with
a control, with a few exceptions (see Notz [1985], Morgan and Wang [2011]).
Nevertheless, the E-optimality does have a statistical interpretation for estimating a sys-
tem of contrastsQT τ in terms of the confidence ellipsoid for QT τ , which represents the amount
of uncertainty about the studied system of contrasts. Under the assumption of normal errors,
the largest eigenvalue of N−1A (ξ) is proportional to the square of the length of the largest
semi-axis of the confidence ellipsoid for QT τ . Therefore, any E-optimal design for comparing
drug doses with the placebo minimizes the length of the largest semi-axis of the confidence
ellipsoid for estimating τ1− τ0, . . . , τn− τ0. This suggests that the E-optimality criterion may
be relevant, as it minimizes the diameter of the confidence ellipsoid.
The E-optimality can also be expressed in the terms of the variances of the drug dose-
placebo contrasts in a straightforward manner, as by Morgan and Wang [2011], even without
the normality assumption. We can write
λmax(N
−1
A (ξ)) = max
‖x‖=1
xTN−1A (ξ)x.
Because N−1A (ξ) is proportional to the variance matrix of the least-squares estimator of Q
T τ
(where QT = (−1n, In)), we have:
Proposition 1. Any standard or extended E-optimal design for comparing the drug doses
with the placebo minimizes the maximum variance among all least-squares estimators of the
drug dose-placebo contrasts of the form
xTQT τ =
n∑
i=1
xiτi − (
n∑
i=1
xi)τ0, where ‖x‖ = 1. (4)
Notz [1985] obtained a class of E-optimal exact block designs in a model without design
constraints and provided two statistical interpretations for these designs, using test treatment-
control contrasts. One of these interpretations (Theorem 3.3) was that the obtained designs
minimized the maximum variance for the contrasts of the form (4). Morgan and Wang [2011]
analysed the relationship as in Proposition 1 further, using weighted optimality criteria (The-
orem 2.1 therein).
Employing the relationship betweenE-optimality and c-optimality (see Pukelsheim and Studden
[1993], Pukelsheim [2006]), it is possible to give one more interpretation of the E-optimality
in our model using the drug dose-placebo contrasts.
Theorem 3. Let ξ be an E-optimal standard or extended design in model (1) for comparing
the drug doses with the placebo. Then, ξ is c-optimal, where c = (−1, 1Tn/n, 0Tt+1)T . That is,
ξ minimizes the variance of the least-squares estimator of
∑
i(τi − τ0)/n.
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Theorem 3 shows that if a standard or extended design is E-optimal for comparing the
doses with the placebo, it minimizes the variance of the average dose effect compared with
the placebo, or the average of the dose effects relative to the placebo. That is, the E-optimal
designs (among other desirable properties) also minimize
Var
( ̂1
n
n∑
i=1
τi − τ0
)
, (5)
where αˆ is the least-squares estimator of α. The other interpretation of the obtained class
of E-optimal exact designs in the standard block model by Notz [1985] was Theorem 3.2, in
which the author showed that the obtained designs minimized (5).
By contrast, the A-optimality criterion, which is often used in test treatment-control
experiments, minimizes the average variance of the least-squares estimators of the contrasts
of interest. That is, it minimizes the average variance for the dose effects compared with the
placebo effect, which can be expressed as minimizing
1
n
n∑
i=1
Var
(
τ̂i − τ0
)
;
compare with (5).
In fact, in the proof of Theorem 3 we show that the E-optimal designs for comparing
drug doses with the placebo minimize hTN−1Q (ξ)h, where h = 1n; i.e., the E-optimal designs
minimize the sum of all elements of the inverse of the information matrix. It follows that
the E-optimal designs for comparing drug doses with the placebo minimize the sum of all
elements of the variance matrix of Q̂T τ . In other words, such designs minimize the sum (or
the average) of all variances Var(τ̂i − τ0), i = 1, . . . , n, and covariances Cov(τ̂i − τ0, τ̂j − τ0),
i 6= j, for the drug dose-placebo comparisons. By contrast, the A-optimal designs minimize
the trace of N−1A (ξ), i.e., the sum (or the average) of all variances Var(τ̂i − τ0).
4 LV -optimality
Senn suggested in his commentary Senn [2009] that what he calls the latest variance (LV )
criterion may be more appropriate to consider, rather than the traditional optimality criteria.
Such a criterion seeks to minimize the variance of the estimator for comparing the latest dose
with the placebo after each cohort. The reasoning is that after each cohort, the experimenter
decides whether or not to continue with the experiment, and this decision is based on the
results obtained so far (the effect of the latest dose relative to the placebo). Therefore, crucial
in the experiment is the variance of the comparison of the latest dose with the placebo, rather
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than all variances based on trials which may not even be performed (if the experiment stops
before all doses were tried).
Since the Senn designs place all the weight in a given cohort on the comparison of the
latest dose with the placebo, intuitively, it is to be expected for them to be LV -optimal. We
formalize this observation as well as the LV -optimality criterion itself.
We denote by Vark(τ̂k − τ0) the variance of the least-squares estimator of τk − τ0 based
on the trials in the first k cohorts, k = 1, . . . , n. Then, an LV -optimal design ξ for comparing
the drug doses with the placebo minimizes each of Var1(τ̂1 − τ0), . . . , Varn(̂τn − τ0) among
all feasible dose-escalation designs. By a feasible design, we mean here a design under which
τ1 − τ0 is estimable after one cohort, τ2 − τ0 is estimable after the first two cohorts etc. We
further remark that the LV -optimality criterion is not defined for a general design problem;
it is strongly tied to the particular properties of the dose-escalation studies.
The criterion of LV -optimality seems to call for a simultaneous multicriterial optimization
(minimizing n variances) which need not have a solution in general; i.e., some trade-off between
the various variances of interest might be needed. However, we show that in our model the
Senn designs do have this strong property, i.e., no other dose-escalation design has any of the
variances in question lower.
Theorem 4. Let ξ be a Senn design. Then, ξ is an LV -optimal standard design.
In the case of extended designs, a design is LV -optimal if it minimizes Var1(τ̂1 − τ0),
. . . , Varn(̂τn − τ0),Varn+1(̂τn − τ0), where Varn+1(̂τn − τ0) is the variance of ̂τn − τ0 once the
entire study has been carried out. Unsurprisingly, the LV -optimal design is the extended
Senn design ξ constructed as follows: ξ is given by the Senn design in the first n cohorts
and its (n + 1)-st cohort is a replication of the n-th cohort (in the sense of the treatment
proportions). Formally,
ξ(0, k) = ξ(k, k) =
1
2(n+ 1)
for k = 1, . . . , n, ξ(0, n+ 1) = ξ(n, n+ 1) =
1
2(n+ 1)
,
and ξ(i, k) = 0 otherwise, see Table 5. We call such a design a highest-dose extended Senn
design.
Note that the extended designs seem to be less meaningful when considering LV -optimality,
as in such a case, the additional cohort is only used to improve the estimate of the effect of
the highest dose compared with the placebo.
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i\k 1 2 3 4 5
0 1/10 1/10 1/10 1/10 1/10
1 1/10 0 0 0 0
2 0 1/10 0 0 0
3 0 0 1/10 0 0
4 0 0 0 1/10 1/10
Table 5: Highest-dose extended Senn design for n = 4 doses. i - treatment number, k - cohort
number
Theorem 5. Let ξ be a highest-dose extended Senn design. Then, ξ is an LV -optimal ex-
tended design.
5 MV -optimality
A widely used optimality criterion in designing experiments for comparing the test treatments
with a control is MV -optimality. A design is MV -optimal if it minimizes the maximum
variance of the least-squares estimators of the contrasts of interest. In the case of comparing
drug doses with the placebo, a design is MV -optimal if it minimizes
Ψ(ξ) = max
1≤i≤n
Var(τ̂i − τ0),
among all ξ ∈ Ξ.
Let us consider the standard designs. Then, as in the LV -optimal case, the Senn designs
are optimal.
Theorem 6. Let ξ be a Senn design. Then, ξ is an MV -optimal standard design for com-
paring drug doses with the placebo.
From numerical studies it seems that unlike the MV -optimal standard designs, the MV -
optimal extended designs do not follow a regular structure that we are able to describe ana-
lytically at this time.
6 Discussion
The optimality results for designs of experiments are highly dependent on the chosen system
of treatment contrasts of interest. The designs obtained in this paper, which are optimal for
the comparison of the drug doses with the placebo, would perform worse than many of the
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designs proposed by Bailey [2009] if the aim of the experiment was to estimate the system
of all pairwise comparisons. Ultimately, the choice of the treatment contrasts of interest lies
upon the experimenters. However, following Senn [2009], we noted that the comparison of
the drug doses with the placebo may be a relevant system of contrasts for the dose-escalation
studies. Therefore, we intended to provide well-performing designs for the case when the dose
effects relative to the placebo are the main focus. In such a case, it seems that the Senn
designs are a reasonable choice.
Another desirable property of the Senn designs is their extremely simple and regular
structure, which ensures a simple construction of exact designs from the approximate Senn
designs, and, which may be even more important, the characterization of these designs for
practical use. Moreover, as noted by Senn [2009], the Senn designs are not ’anticipatory’. That
is, due to their self-similar structure, their optimality properties hold even when the study is
stopped and thus the entire design is not performed - e.g., unlike the design given in Table
3 which is E-optimal only if the entire experiment is carried out. Such ’non-anticipatory’
property is crucial in the LV -optimality of the Senn designs.
If the extra cohort is considered and the main focus is on the comparisons of the doses
with the placebo, one may choose one of the two extensions of the Senn designs that are
provided in this paper. These extensions have forms that are rather simple to describe, and
they inherit the optimality properties of the Senn designs if the study is stopped before the
entire design is carried out. Alternatively, we provided an entire class of E-optimal extended
designs described by simple (linear) conditions, which allows one to calculate a design that
is optimal in this class with respect to a secondary criterion, if some secondary criterion is
deemed relevant.
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Appendix
Proof of Theorem 1. The Senn design ξ satisfies r = (1/2, 1Tn/(2n))
T , X = (1n, In)
T /(2n) and
thus Z = In/(2n). Note that ξ is connected (see Eccleston and Hedayat [1974]) and therefore
feasible. Then, equation (3) yields that NA = In/(4n), which has the smallest eigenvalue
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1/(4n). The proof of Theorem 6 by Rosa and Harman [2016] states that when there are no
design constraints, the optimal value of the E-criterion is 1/[4(v− 1)], where v is the number
of treatments. In our model, v = n + 1 and thus the E-optimal value is 1/(4n), which the
Senn design attains.
Now, consider the converse part. For a feasible design ξ to be E-optimal, it must have
the smallest eigenvalue equal to that of the Senn design, which coincides with the optimal
value of E-optimality criterion in the model without the design constraints. Thus, such ξ is
E-optimal in the model without design constraints, and from Lemma 1 it follows that ξ must
satisfy
r0(ξ) = 1/2, ri(ξ) = 1/(2n), i = 1, . . . , n; (6)
hence r = (1/2, 1Tn/(2n))
T .
Observe that NA(ξ) = C = In/(2n) − nZZT , as defined in (2). Then, the smallest
eigenvalue λmin of NA(ξ) satisfies λmin = 1/(2n)−nµmax, where µmax is the largest eigenvalue
of ZZT . Let us denote the columns of matrix Z = (zij) by z1, . . . , zn. Then,
µmax = max
‖u‖=1
uTZZTu = max
‖u‖=1
‖ZTu‖2 = max
‖u‖=1
n∑
j=1
(zTj u)
2,
and for the particular choice of u = 1n/
√
n, we obtain
µmax ≥ 1
n
n∑
j=1
(1Tnzj)
2 =
1
n
n∑
j=1
( n∑
i=1
zij
)2
=
1
n
n∑
j=1
q2j ,
where qj :=
∑n
i=1 zij , j = 1, . . . , n. From (i) it follows that qj = n
−1 − ξ(0, j), and (6) yields∑
j qj = 1−1/2 = 1/2. Therefore, µmax is not smaller than the optimal value of the following
convex optimization problem:
min
q≥0
1
n
n∑
j=1
q2j subject to
n∑
j=1
qj =
1
2
. (7)
Because the objective function of (7) is strictly convex on the affine hyperplane formed by the
equality constraints and invariant with respect to the permutations of q1, . . . , qn, the single
optimal solution q∗ of (7) satisfies q∗1 = · · · = q∗n = 1/(2n). Therefore, the optimal value of (7)
is 1/(4n2). It follows that if q does not satisfy q1 = · · · = qn = 1/(2n), then µmax > 1/(4n2).
Therefore, the smallest eigenvalue λmin of NA(ξ) for such ξ satisfies λmin < 1/(4n), and thus
ξ is not E-optimal. Hence, any E-optimal design ξ must satisfy q1 = · · · = qn = 1/(2n), i.e.,
ξ(0, 1) = · · · = ξ(0, n) = 1/(2n).
From (6) and (i), ξ needs to satisfy ri = 1/(2n) for i > 0 and sk =
∑
i ξ(i, k) = 1/n for
all k. Using (ii), because ξ(n, k) can be non-zero only for k = n, we obtain ξ(n, n) = 1/(2n).
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Since ξ(0, n) = 1/(2n), we have ξ(i, n) = 0 for 0 < i < n. Then, ξ(n − 1, k) is non-zero only
for k = n− 1, which yields ξ(n− 1, n− 1) = 1/(2n), ξ(i, n− 1) = 0 for 0 < i < n− 1, etc. It
follows that the single E-optimal standard design for given n is the Senn design.
Proof of Theorem 2. Let ξ be a design that satisfies the conditions of Theorem 2. First,
observe that ξ is connected (see Eccleston and Hedayat [1974]) and therefore feasible. The
partitions of Mτ defined in (2) satisfy z = 1n+1/(2(n + 1)), X1n+1 = r =
(
1/2, 1Tn/(2n)
)T
,
Z1n+1 = 1n/(2n), X
T 1n+1 = 1n+1/(n+ 1) and Z
T 1n = 1n+1/(2(n+ 1)).
Thus, NA = C = In/(2n)−(n+1)ZZT . Moreover,NA1n = 1n/(4n), i.e., 1n is an eigenvec-
tor of NA with eigenvalue λ1 = 1/(4n), which is, analogously to the proof of Theorem 1, equal
to the optimal smallest eigenvalue in the model without constraints, see Rosa and Harman
[2016]. Therefore, to prove that ξ is E-optimal, it suffices to prove that λ1 is the smallest
eigenvalue of NA. The smallest eigenvalue of NA satisfies λmin(NA) = 1/(2n)− (n+ 1)µmax,
where µmax is the largest eigenvalue of ZZ
T .
Let Zˆ =
(
2nZT , 1n+1/(n+ 1)
)
. The matrix Zˆ satisfies Zˆ1n+1 = 1n+1 and 1
T
n+1Zˆ = 1
T
n+1,
i.e., Zˆ is doubly stochastic. Using the Birkhoff-von Neumann theorem, we obtain that
Zˆ =
∑
pi∈Pn+1
αpiPpi,
where αpi ≥ 0 for all pi,
∑
pi αpi = 1, Pn+1 denotes the set of all permutations of n + 1
elements and Ppi is the permutation matrix given by pi. Let us partition the matrices Ppi as
Ppi =
(
P˜pi, vpi
)
, where P˜pi is an (n+ 1)× n matrix. Then,
2nZT =
∑
pi∈Pn+1
αpiP˜pi, Z =
1
2n
∑
pi∈Pn+1
αpiP˜
T
pi ,
1
n+ 1
1n+1 =
∑
pi∈Pn+1
αpivpi.
Let P
(i)
n+1 be the set of all permutations pi of n + 1 elements, the corresponding matrices of
which have their last column equal to ei, i.e., pi(n+ 1) = i. Then, because the last column of
Zˆ is 1n+1/(n+ 1), we have
∑
pi∈P
(i)
n+1
αpi = 1/(n+ 1).
The largest eigenvalue µmax of ZZ
T is identical to the largest eigenvalue of ZTZ; therefore,
it satisfies
µmax = max
‖u‖=1
uTZTZu = max
‖u‖=1
‖Zu‖2 = 1
4n2
max
‖u‖=1
∥∥∥ ∑
pi∈Pn+1
αpiP˜
T
pi u
∥∥∥2
=
1
4n2
max
‖u‖=1
∥∥∥ n+1∑
i=1
∑
pi∈P
(i)
n+1
αpiP˜
T
pi u
∥∥∥2 ≤ n+ 1
4n2
max
‖u‖=1
n+1∑
i=1
∥∥∥ ∑
pi∈P
(i)
n+1
αpiP˜
T
pi u
∥∥∥2,
where the last inequality follows from the fact that ‖∑ki=1 xi‖2 ≤ k∑ki=1‖xi‖2 for any vectors
x1, . . . , xk.
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Let i ∈ {1, . . . , n+ 1}. Then the set of the extremal points of the convex set
Ki :=
{ ∑
pi∈P
(i)
n+1
αpiP˜
T
pi u
∣∣∣αpi ≥ 0 for pi ∈ P(i)n+1, ∑
pi∈P
(i)
n+1
αpi =
1
n+ 1
}
is a subset of {P˜Tpi u/(n + 1) |pi ∈ P(i)n+1}, and the convex function ‖x‖2, x ∈ Ki, attains its
maximum in at least one of the extremal points of Ki. It follows that∥∥∥ ∑
pi∈P
(i)
n+1
αpiP˜
T
pi u
∥∥∥2 ≤ max
pii∈P
(i)
n+1
∥∥∥ 1
n+ 1
P˜Tpiiu
∥∥∥2 = 1
(n+ 1)2
max
pii∈P
(i)
n+1
‖P˜Tpiiu‖2;
thus,
µmax ≤ 1
4n2(n+ 1)
max
‖u‖=1
max
pi1∈P
(1)
n+1,...,pin+1∈P
(n+1)
n+1
n+1∑
i=1
‖P˜Tpiiu‖2.
Consider pi1 ∈ P(1)n+1, . . . , pin+1 ∈ P(n+1)n+1 and u ∈ Rn+1, ‖u‖ = 1, that maximize
∑n+1
i=1 ‖P˜Tpiiu‖2,
and let us denote vi = (vi,1, . . . , vi,n)
T := P˜Tpiiu, i = 1, . . . , n+ 1. Then, µmax satisfies
µmax ≤ 1
4n2(n+ 1)
n+1∑
i=1
n∑
j=1
v2i,j =
1
4n2(n+ 1)
n+1∑
i=1
S,
where S is the sum of squares of all elements of vectors v1, . . . , vn+1. For each i ∈ {1, . . . , n+1},
the vector vi = P˜
T
pii
u consists of all elements of u except ui; therefore, u
2
i occurs n-times in S.
Hence, S = nu21 + · · ·+ nu2n+1 = n‖u‖2 = n and it follows that µmax ≤ (4n(n+ 1))−1. Since
µmax ≤ (4n(n+1))−1, the smallest eigenvalue of NA is at least 1/(2n)− (n+1)/(4n(n+1)) =
1/(4n) and thus λ1 is indeed the smallest eigenvalue of NA.
To prove the converse part, note that similarly to Theorem 1, from Lemma 1 it follows
that for ξ to attain the optimal value of E-criterion, 1/(4n), it must satisfy (6). Let ξ be
a design that satisfies (6) but does not satisfy ξ(0, k) = 1/(2(n + 1)), k = 1, . . . , n + 1. Let
qj := 1/(n+1)− ξ(0, j), j = 1, . . . , n+1; hence,
∑
j qj = 1−1/2 = 1/2. Then, analogously to
the proof of Theorem 1, the largest eigenvalue µmax of ZZ
T is not smaller than the optimal
value of the following convex optimization problem:
min
q≥0
1
n
n+1∑
j=1
q2j subject to
n+1∑
j=1
qj =
1
2
,
which has a unique optimal solution q∗ satisfying q∗1 = · · · = q∗n+1 = (2(n + 1))−1, and
the optimal value is (4n(n + 1))−1. It follows that if q does not satisfy q1 = · · · = qn+1 =
(2(n+ 1))−1, then µmax > (4n(n + 1))
−1. Therefore, the smallest eigenvalue λmin of NA for
such ξ satisfies λmin < (4n)
−1 and thus ξ is not E-optimal.
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In the proof of Theorem 3, Theorems 7.21 (the General Equivalence Theorem for E-
optimality) and 7.23 by Pukelsheim [2006] will be used.
Lemma 2 (Theorem 7.21 from Pukelsheim [2006]). A feasible design ξ with its moment
matrix M and information matrix NA is E-optimal for estimating A
Tβ if and only if there
exist a generalized inverse G of M and a non-negative definite matrix E, tr(E) = 1, such that
tr(M(ξ˜)GANAENAA
TGT ) ≤ λmin(NA) for all ξ˜ ∈ Ξ. (8)
Lemma 3 (Theorem 7.23 from Pukelsheim [2006]). Let ξ be a feasible design for ATβ with
its information matrix NA and let h, ‖h‖ = 1, be an eigenvector of NA corresponding to the
smallest eigenvalue of NA. Then, ξ is E-optimal for A
Tβ and E = hhT satisfies (8) if and
only if ξ is c-optimal, where c = Ah. If the smallest eigenvalue of NA has multiplicity 1, ξ is
E-optimal for ATβ if and only if it is c-optimal, where c = Ah.
Proof of Theorem 3. Recall that AT = (QT , 0n×(t+1)) andQ
T = (−1n, In). Let c˜ := (−1, 1Tn/n, 0Tt+1)T .
For the (standard) Senn design, we have NA = In/(4n). Let us choose
G =
[
M−τ −M−τ M12M−22
−M−22MT12M−τ M−22 +M−22MT12M−τ M12M−22
]
, (9)
where
M−τ =
[
0 0Tn
0n 4nIn
]
and M−22 =
[
0 0Tn
0n nIn
]
, (10)
and E = 1n1
T
n/n = hh
T , where h = 1n/
√
n. The matrix G is indeed a generalized inverse
of M , see Theorem 9.6.1 by Harville [1997]. Then, it is possible to verify that there is
equality in (8) for any permissible design ξ˜. Therefore, Lemma 3 implies that any E-optimal
standard design (i.e., Senn design) is also c-optimal, where c = A1n/
√
n, which is equivalent
to A1n/n =: c˜.
Let ξ be an E-optimal extended design for comparing the treatments with the placebo,
with its moment matrix M and information matrix NA. Then, h = 1n/
√
n is an eigenvector
of NA corresponding to the smallest eigenvalue λmin = 1/(4n) (see the proof of Theorem 2).
The left-hand side of the normality inequality (8) for E = hhT and a given ξ˜ ∈ Ξ becomes
tr(M˜GANAhh
TNAA
TGT ) = λ2minh
TATGT M˜GAh =
1
16n3
1TnA
TGT M˜GA1n, (11)
where M˜ := M(ξ˜). Moreover, A1n = (−n, 1Tn , 0Tn+2)T .
Recall the partitioning of Mτ and X defined in (2). Let the generalized inverse G of M
be given by (9), where
M−τ =
[
0 0Tn
0n C
−1
]
.
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Then,
GA1n =

0
C−11n
0
−(n+ 1)ZTC−11n
 .
Since C−1 = N−1A , we obtain C
−11n = 4n1n. Then, GA1n = (0, 4n1
T
n , 0,−(n+1)4n1TnZ)T =
(0, 4n1Tn , 0,−2n1Tn+1)T , because ZT 1n = 1n+1/(2(n+ 1)).
Let us partition M˜ = M(ξ˜) using α˜, b˜, z˜ and Z˜ as in (2), and let us denote r˜ = r(ξ˜).
Then, (11) becomes
1
16n3
(
(0, 4n1Tn )M˜11
(
0
4n1n
)
+(0,−2n1Tn+1)M˜22
(
0
−2n1n+1
)
+2(0, 4n1Tn)M˜12
(
0
−2n1n+1
))
,
which is equal to
1
16n3
(
16n2
∑
i>0
r˜i + 4n
2 − 16n2
∑
i>0
r˜i
)
=
1
4n
= λmin,
because Z˜1n+1 = (r˜1, . . . , r˜n)
T . Therefore, the left-hand side of (8) is always equal to the
right-hand side. Hence, Lemma 3 yields that ξ is c˜-optimal.
Proof of Theorem 4. Let ξ be a standard design and let k ∈ {1, . . . , n}. The variance ma-
trix of the least-squares estimator of the contrasts of interest, Varξ(Q̂T τ ), is proportional to
N−1A (ξ) = Q
TM−τ Q. The variance calculated from the first k cohorts under a given design ξ,
Vark(τ̂k − τ0), can be obtained from a stage-k ’design’ ξ(k). Such a design is given by deleting
all the trials in cohorts k + 1, . . . , n from ξ, i.e., for any i: ξ(k)(i, j) = ξ(i, j) for j ≤ k and
ξ(k)(i, j) = 0 for j > k. Note that for k < n, ξ(k) is not a proper approximate design, because
all of its elements do not sum to 1, indicating that the trials in the future cohorts are ignored.
The stage-k moment matrix M (k) given by ξ(k) satisfies M
(k)
11 = diag(r0, . . . , rk, 0
T
n−k),
M
(k)
12 =


r0
...
rk


ξ(0, 1) ξ(0, 2) . . . ξ(0, k)
ξ(1, 1) ξ(1, 2) . . . ξ(1, k)
0 ξ(2, 2) . . . ξ(2, k)
...
...
...
0 0 . . . ξ(k, k)

0(k+1)×(t−k)
0n−k 0(n−k)×k 0(n−k)×(t−k)

and
M
(k)
22 =

1 1Tk /n 0
T
t−k
1k/n Ik/n 0k×(t−k)
0(t−k) 0(t−k)×k 0(t−k)×(t−k)
 ,
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where t = n, because we are considering standard designs. Then, the latest varianceVark(τ̂k − τ0)
is proportional to dk(ξ) := (e
T
k+1 − eT1 , 0Tt+1)
(
M (k)
)−
(eTk+1 − eT1 , 0Tt+1)T , where e1 and ek+1
are elementary unit vectors of length n+ 1.
To calculate dk(ξ), we disregard cohorts k + 1, . . . , n and we are not allowed to use doses
k + 1, . . . , n in the first k cohorts. Such a model coincides with model (1), where n = k
and a design ξ′ given by ξ for doses 0, . . . , k and cohorts 1, . . . , k. Then the latest variance
under ξ is proportional to the inverse of the value of the c-optimality criterion for ξ′, which is
Φc(ξ
′) =
(
cTM−(ξ′)c
)−1
for cT = (eTn+1− eT1 , 0Tn+1). Therefore, without loss of generality, we
may assume that k = n and prove that the Senn design has the highest value of c-optimality
criterion, where cT = (eTn+1 − eT1 , 0Tn+1).
The General Equivalence Theorem in the case of c-optimality becomes (Corollary 5.1 from
Pukelsheim [1980]): Let M be a set of competing moment matrices. The moment matrix
M ∈ M is c-optimal in M if and only if there exists a generalized inverse G of M , such that
cTGTBGc ≤ cTM−c for all B ∈ M.
Now, let ξ be a Senn design, let c = (eTn+1 − eT1 , 0Tn+1)T and let us denote M := M(ξ).
Then, r = 2−1
(
1, 1Tn/n)
T , X = (2n)−1
(
1n, In
)T
,
Mτ =
1
4n
[
n −1Tn
−1n In
]
, and let M−τ =
[
0 0Tn
0n 4nIn
]
.
Thus, cTM−c = (en+1 − e1)TM−τ (en+1 − e1) = 4n.
Let G be given by (9), where M−22 is given by (10). It follows that
Gc =

0 0Tn
G12
0n 4nIn
0 0Tn
G22
0n −2nIn


−1
0n−1
1
0n+1
 =

0n
4n
0n
−2n

and therefore, for any feasible design ξ′ satisfying conditions (i), (ii), we have
cTGTM(ξ′)Gc =
[
0Tn 4n 0
T
n −2n
]
diag(r′) r′ X ′
r′
T
1 1Tn/n
X ′
T
1n/n In/n


0n
4n
0n
−2n

= (4n)2r′n + (−2n)2
1
n
+ 2× 4n(−2n)ξ′(n, n) = 4n,
because ξ′(n, n) = r′n. Therefore, any design satisfying conditions (i), (ii) satisfies the desired
inequality 4n ≤ cTM−c = 4n. Hence, for any k, the Senn design attains the minimum possible
latest variance.
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Proof of Theorem 5. For the first n latest variances, the argument is the same as in the
standard design case, see the proof of Theorem 4. Optimality of ξ with respect to the (n+1)-
st latest variance can be proved by using the General Equivalence Theorem for c-optimality,
c = en+1 − e1.
Design ξ satisfies
X =
1
2(n+ 1)

1Tn−1 1
T
2
In−1 0(n−1)×2
0Tn−1 1
T
2
 , r =

1
2
1
2(n+1)1n−1
1
n+1
 .
Then,
Mτ =

1/4 − 14(n+1)1Tn−1 − 12(n+1)
− 14(n+1)1n−1 14(n+1)In−1 0n−1
− 12(n+1) 0Tn−1 12(n+1)

and
M−τ = 2(n+ 1)

0 0Tn−1 0
0n−1 2In−1 0n−1
0 0Tn−1 1

is a generalized inverse of Mτ . Hence, c
TM−c = 2(n+ 1). Furthermore,
M−22 =
[
0 0Tn+1
0n+1 (n+ 1)In+1
]
is a generalized inverse of M22. By choosing the generalized inverse G of M given by (9),
after some calculations similar to the proof of Theorem 4, the normality inequality becomes
cTGTM(ξ′)Gc = 2(n+ 1) ≤ cTM−c = 2(n+ 1) for any design ξ′ satisfying (i), (ii).
Proof of Theorem 6. Let ξ be a standard design and let us denote vi(ξ) := Varξ(τ̂i − τ0),
i = 1, . . . , n. Then, Ψ(ξ) = maxi vi(ξ). Theorem 4 states that the Senn design ξS is LV -
optimal, i.e., dk(ξ) ≥ dk(ξS) for all k = 1, . . . , n. If k = n, then the latest variance and the
final variance (the variance when the entire design is carried out) coincide. It follows that
vn(ξ) ≥ vn(ξS).
In the proof of Theorem 1, we can observe that QTM−τ (ξS)Q = 4nIn. It follows that
v1(ξS) = . . . = vn(ξS) ≈ 4n and thus Ψ(ξS) = vn(ξS). Because vn(ξ) ≥ vn(ξS), we obtain
Ψ(ξ) ≥ vn(ξ) ≥ Ψ(ξS).
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